Share Price and Basic Stock Data
Last Updated: November 22, 2025, 10:40 am
| PEG Ratio | -8.44 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Auro Laboratories Ltd operates in the pharmaceuticals sector and is currently priced at ₹258, with a market capitalization of ₹161 Cr. Over the past fiscal years, the company has exhibited fluctuating revenue patterns. In FY 2023, sales stood at ₹52.89 Cr, a slight increase from ₹50.87 Cr in FY 2022. However, the most recent data indicates a significant drop in revenue for FY 2025, which reported ₹19.40 Cr. Quarterly sales figures from Jun 2022 to Sep 2023 show variability, with a peak in Dec 2023 at ₹17.98 Cr, following a decline to ₹10.18 Cr in Jun 2023. These trends highlight a potential vulnerability in maintaining consistent revenue streams, particularly in the face of competitive pressures within the pharmaceutical industry. The trailing twelve months (TTM) revenue is ₹22.06 Cr, indicating a challenging environment for growth. The volatility in quarterly sales can be a concern for investors looking for stability in earnings.
Profitability and Efficiency Metrics
Auro Laboratories’ profitability metrics reflect a mixed performance. The operating profit margin (OPM) reported a high of 22.69% in Dec 2023, but it has since declined, culminating at 1.08% in Mar 2025. The net profit margin also exhibited variability, with a peak of 9.47% in Mar 2025 compared to 14.52% in Mar 2024. The return on equity (ROE) stood at 4.33%, while the return on capital employed (ROCE) was lower at 3.85%, both indicating limited efficiency in generating profits from shareholder equity and capital. The interest coverage ratio (ICR) of 3.75x suggests that Auro Laboratories can comfortably meet its interest obligations, though the declining trends in operating and net profit margins raise concerns about the long-term profitability of the business. The cash conversion cycle (CCC) of 76.01 days indicates a reasonable efficiency in managing cash flows, though the increasing working capital days highlight potential liquidity issues.
Balance Sheet Strength and Financial Ratios
Auro Laboratories’ balance sheet presents a mixed picture. The company reported no borrowings, which suggests a conservative approach to financing; however, this also raises questions about leverage and growth potential. The price-to-book value (P/BV) ratio stands at 3.34x, indicating that the market values the company significantly higher than its book value, which was ₹68.94 per share as of Mar 2025. The current ratio of 0.99 suggests that the company is operating close to a liquidity threshold, which could pose risks in times of financial strain. The total debt-to-equity ratio of 1.05 indicates that Auro Laboratories has a higher reliance on debt compared to equity, which could impact its financial flexibility. Overall, while the absence of debt is a positive, the reliance on equity and the liquidity position may hinder growth opportunities in competitive market conditions.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Auro Laboratories reveals a stable yet concentrated ownership structure. Promoters hold 52.17% of the equity, indicating a strong insider commitment to the company. However, the presence of domestic institutional investors (DIIs) is negligible at 0.01%, while public shareholders account for 47.82%. The number of shareholders has gradually declined from 11,135 in Dec 2022 to 8,860 by Jun 2025, reflecting a potential diminishing interest among retail investors. This decline in shareholder numbers could raise concerns regarding investor confidence and market perception. On the positive side, a high promoter stake often signals alignment of interests between management and shareholders, which is crucial for long-term strategic goals. However, the lack of institutional backing may limit the stock’s visibility and attractiveness to larger investors.
Outlook, Risks, and Final Insight
The outlook for Auro Laboratories is contingent on its ability to stabilize revenue and enhance profitability metrics. The recent decline in quarterly sales and profitability ratios indicates an urgent need for strategic interventions to counteract market headwinds. Key risks include the volatility in sales and margins, which could lead to cash flow challenges, particularly given the low liquidity position. Furthermore, the reliance on equity financing without leveraging debt could limit growth opportunities in an increasingly competitive pharmaceutical landscape. On the other hand, the promoter’s significant stake and conservative financial policies provide a foundation for potential recovery. Auro Laboratories must focus on operational efficiencies and explore avenues for revenue diversification to mitigate risks and restore investor confidence, thereby positioning itself for sustainable growth in the future.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Auro Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 159 Cr. | 127 | 247/84.3 | 35.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,497 Cr. | 413 | 479/192 | 93.1 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.6 Cr. | 44.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 39.5 Cr. | 27.0 | 29.1/17.0 | 94.1 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,140.56 Cr | 1,177.13 | 52.88 | 202.41 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11.19 | 12.56 | 15.62 | 13.52 | 10.18 | 13.41 | 17.98 | 12.06 | 5.72 | 3.10 | 3.05 | 7.40 | 2.77 |
| Expenses | 10.62 | 11.54 | 15.17 | 11.17 | 9.02 | 10.38 | 13.90 | 9.65 | 4.39 | 2.38 | 2.60 | 6.59 | 2.74 |
| Operating Profit | 0.57 | 1.02 | 0.45 | 2.35 | 1.16 | 3.03 | 4.08 | 2.41 | 1.33 | 0.72 | 0.45 | 0.81 | 0.03 |
| OPM % | 5.09% | 8.12% | 2.88% | 17.38% | 11.39% | 22.60% | 22.69% | 19.98% | 23.25% | 23.23% | 14.75% | 10.95% | 1.08% |
| Other Income | 0.05 | -0.16 | 0.43 | 0.62 | 0.36 | 0.32 | 0.42 | 0.40 | 0.20 | 0.31 | 0.14 | 0.13 | 0.42 |
| Interest | 0.26 | 0.32 | 0.10 | 0.13 | 0.27 | 0.35 | 0.44 | -0.32 | 0.25 | 0.28 | 0.25 | 0.30 | 0.28 |
| Depreciation | 0.25 | 0.25 | 0.27 | 0.30 | 0.27 | 0.27 | 0.27 | 0.28 | 0.27 | 0.27 | 0.27 | 0.29 | 0.27 |
| Profit before tax | 0.11 | 0.29 | 0.51 | 2.54 | 0.98 | 2.73 | 3.79 | 2.85 | 1.01 | 0.48 | 0.07 | 0.35 | -0.10 |
| Tax % | 27.27% | 27.59% | 27.45% | 29.53% | 27.55% | 27.84% | 27.70% | 18.60% | 24.75% | 25.00% | 28.57% | -11.43% | 0.00% |
| Net Profit | 0.08 | 0.21 | 0.37 | 1.78 | 0.71 | 1.97 | 2.73 | 2.32 | 0.75 | 0.36 | 0.05 | 0.39 | -0.11 |
| EPS in Rs | 0.13 | 0.34 | 0.59 | 2.86 | 1.14 | 3.16 | 4.38 | 3.72 | 1.20 | 0.58 | 0.08 | 0.63 | -0.18 |
Last Updated: August 19, 2025, 11:00 pm
Below is a detailed analysis of the quarterly data for Auro Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2.77 Cr.. The value appears to be declining and may need further review. It has decreased from 7.40 Cr. (Mar 2025) to 2.77 Cr., marking a decrease of 4.63 Cr..
- For Expenses, as of Jun 2025, the value is 2.74 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.59 Cr. (Mar 2025) to 2.74 Cr., marking a decrease of 3.85 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.03 Cr.. The value appears to be declining and may need further review. It has decreased from 0.81 Cr. (Mar 2025) to 0.03 Cr., marking a decrease of 0.78 Cr..
- For OPM %, as of Jun 2025, the value is 1.08%. The value appears to be declining and may need further review. It has decreased from 10.95% (Mar 2025) to 1.08%, marking a decrease of 9.87%.
- For Other Income, as of Jun 2025, the value is 0.42 Cr.. The value appears strong and on an upward trend. It has increased from 0.13 Cr. (Mar 2025) to 0.42 Cr., marking an increase of 0.29 Cr..
- For Interest, as of Jun 2025, the value is 0.28 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.30 Cr. (Mar 2025) to 0.28 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Jun 2025, the value is 0.27 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.29 Cr. (Mar 2025) to 0.27 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.10 Cr.. The value appears to be declining and may need further review. It has decreased from 0.35 Cr. (Mar 2025) to -0.10 Cr., marking a decrease of 0.45 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be increasing, which may not be favorable. It has increased from -11.43% (Mar 2025) to 0.00%, marking an increase of 11.43%.
- For Net Profit, as of Jun 2025, the value is -0.11 Cr.. The value appears to be declining and may need further review. It has decreased from 0.39 Cr. (Mar 2025) to -0.11 Cr., marking a decrease of 0.50 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.18. The value appears to be declining and may need further review. It has decreased from 0.63 (Mar 2025) to -0.18, marking a decrease of 0.81.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:52 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.74 | 32.65 | 27.91 | 35.47 | 40.79 | 46.82 | 43.79 | 54.25 | 50.87 | 52.89 | 53.64 | 19.40 | 22.06 |
| Expenses | 30.95 | 29.71 | 25.11 | 31.03 | 34.43 | 39.83 | 37.51 | 43.01 | 46.24 | 48.50 | 42.96 | 16.00 | 18.42 |
| Operating Profit | 2.79 | 2.94 | 2.80 | 4.44 | 6.36 | 6.99 | 6.28 | 11.24 | 4.63 | 4.39 | 10.68 | 3.40 | 3.64 |
| OPM % | 8.27% | 9.00% | 10.03% | 12.52% | 15.59% | 14.93% | 14.34% | 20.72% | 9.10% | 8.30% | 19.91% | 17.53% | 16.50% |
| Other Income | 0.06 | 0.24 | 0.42 | 0.53 | 0.51 | 0.96 | 0.97 | 0.76 | 1.09 | 0.94 | 1.50 | 0.66 | 1.67 |
| Interest | 1.53 | 1.66 | 1.66 | 1.18 | 1.21 | 0.87 | 0.58 | 0.46 | 0.83 | 0.81 | 0.74 | 1.08 | 1.79 |
| Depreciation | 0.74 | 0.72 | 0.68 | 0.86 | 0.93 | 1.01 | 1.02 | 1.04 | 1.02 | 1.07 | 1.09 | 1.10 | 1.48 |
| Profit before tax | 0.58 | 0.80 | 0.88 | 2.93 | 4.73 | 6.07 | 5.65 | 10.50 | 3.87 | 3.45 | 10.35 | 1.88 | 2.04 |
| Tax % | 0.00% | 0.00% | 0.00% | 72.01% | 25.16% | 27.51% | 27.96% | 31.62% | 26.61% | 28.99% | 24.64% | 2.13% | |
| Net Profit | 0.58 | 0.80 | 0.88 | 0.82 | 3.53 | 4.40 | 4.05 | 7.18 | 2.84 | 2.44 | 7.79 | 1.84 | 1.05 |
| EPS in Rs | 0.93 | 1.28 | 1.41 | 1.32 | 5.66 | 7.06 | 6.50 | 11.52 | 4.56 | 3.91 | 12.50 | 2.95 | 1.69 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 37.93% | 10.00% | -6.82% | 330.49% | 24.65% | -7.95% | 77.28% | -60.45% | -14.08% | 219.26% | -76.38% |
| Change in YoY Net Profit Growth (%) | 0.00% | -27.93% | -16.82% | 337.31% | -305.84% | -32.60% | 85.24% | -137.73% | 46.36% | 233.35% | -295.64% |
Auro Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -15% |
| 3 Years: | -27% |
| TTM: | -67% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -15% |
| 3 Years: | -13% |
| TTM: | -91% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 34% |
| 5 Years: | 33% |
| 3 Years: | 42% |
| 1 Year: | 23% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 13% |
| 3 Years: | 11% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 2:31 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 46.95 | 94.80 | 66.04 | 79.13 | 74.90 | 66.26 | 48.18 | 49.12 | 97.65 | 85.57 | 91.11 | 176.67 |
| Inventory Days | 115.33 | 89.37 | 86.72 | 21.65 | 22.00 | 42.98 | 60.54 | 32.60 | 47.32 | 120.27 | 113.24 | 145.45 |
| Days Payable | 62.97 | 56.12 | 72.03 | 80.26 | 78.26 | 66.19 | 70.67 | 73.51 | 54.12 | 117.41 | 85.34 | 246.11 |
| Cash Conversion Cycle | 99.30 | 128.05 | 80.73 | 20.52 | 18.64 | 43.05 | 38.04 | 8.20 | 90.86 | 88.44 | 119.01 | 76.01 |
| Working Capital Days | 19.15 | 39.13 | 26.68 | 67.20 | 64.70 | 63.46 | 51.09 | 29.40 | 36.59 | 104.28 | 35.86 | -14.30 |
| ROCE % | 9.43% | 10.74% | 11.21% | 23.06% | 32.51% | 29.11% | 24.84% | 38.87% | 12.20% | 9.92% | 20.38% | 3.85% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 |
| Diluted EPS (Rs.) | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 |
| Cash EPS (Rs.) | 4.71 | 14.26 | 5.64 | 6.20 | 13.18 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 68.94 | 67.32 | 54.87 | 50.58 | 45.86 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 68.94 | 67.32 | 54.87 | 50.58 | 45.86 |
| Revenue From Operations / Share (Rs.) | 31.12 | 86.06 | 84.87 | 81.61 | 87.05 |
| PBDIT / Share (Rs.) | 6.51 | 19.53 | 8.56 | 9.17 | 19.25 |
| PBIT / Share (Rs.) | 4.75 | 17.78 | 6.83 | 7.54 | 17.59 |
| PBT / Share (Rs.) | 3.02 | 16.60 | 5.53 | 6.21 | 16.86 |
| Net Profit / Share (Rs.) | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 |
| PBDIT Margin (%) | 20.92 | 22.69 | 10.08 | 11.24 | 22.11 |
| PBIT Margin (%) | 15.27 | 20.66 | 8.05 | 9.24 | 20.20 |
| PBT Margin (%) | 9.69 | 19.28 | 6.51 | 7.61 | 19.36 |
| Net Profit Margin (%) | 9.47 | 14.52 | 4.61 | 5.59 | 13.23 |
| Return on Networth / Equity (%) | 4.27 | 18.57 | 7.14 | 9.02 | 25.11 |
| Return on Capital Employeed (%) | 3.82 | 17.93 | 11.25 | 13.49 | 32.80 |
| Return On Assets (%) | 1.85 | 9.08 | 4.36 | 5.17 | 17.13 |
| Long Term Debt / Equity (X) | 0.76 | 0.43 | 0.05 | 0.02 | 0.07 |
| Total Debt / Equity (X) | 1.05 | 0.62 | 0.18 | 0.02 | 0.07 |
| Asset Turnover Ratio (%) | 0.20 | 0.75 | 0.95 | 1.05 | 1.46 |
| Current Ratio (X) | 0.99 | 1.29 | 1.97 | 1.87 | 3.32 |
| Quick Ratio (X) | 0.82 | 0.94 | 1.32 | 1.66 | 3.02 |
| Inventory Turnover Ratio (X) | 0.85 | 2.90 | 4.66 | 9.92 | 8.30 |
| Interest Coverage Ratio (X) | 3.75 | 16.55 | 6.55 | 6.92 | 26.18 |
| Interest Coverage Ratio (Post Tax) (X) | 2.70 | 11.59 | 4.00 | 4.44 | 16.66 |
| Enterprise Value (Cr.) | 188.07 | 125.03 | 37.80 | 50.97 | 38.05 |
| EV / Net Operating Revenue (X) | 9.70 | 2.33 | 0.71 | 1.00 | 0.70 |
| EV / EBITDA (X) | 46.33 | 10.27 | 7.09 | 8.91 | 3.17 |
| MarketCap / Net Operating Revenue (X) | 7.41 | 1.87 | 0.64 | 1.23 | 0.93 |
| Price / BV (X) | 3.34 | 2.39 | 0.99 | 1.98 | 1.77 |
| Price / Net Operating Revenue (X) | 7.41 | 1.87 | 0.64 | 1.23 | 0.93 |
| EarningsYield | 0.01 | 0.07 | 0.07 | 0.04 | 0.14 |
After reviewing the key financial ratios for Auro Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 5. It has decreased from 12.50 (Mar 24) to 2.95, marking a decrease of 9.55.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 5. It has decreased from 12.50 (Mar 24) to 2.95, marking a decrease of 9.55.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.71. This value is within the healthy range. It has decreased from 14.26 (Mar 24) to 4.71, marking a decrease of 9.55.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.94. It has increased from 67.32 (Mar 24) to 68.94, marking an increase of 1.62.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.94. It has increased from 67.32 (Mar 24) to 68.94, marking an increase of 1.62.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 31.12. It has decreased from 86.06 (Mar 24) to 31.12, marking a decrease of 54.94.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 6.51. This value is within the healthy range. It has decreased from 19.53 (Mar 24) to 6.51, marking a decrease of 13.02.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.75. This value is within the healthy range. It has decreased from 17.78 (Mar 24) to 4.75, marking a decrease of 13.03.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.02. This value is within the healthy range. It has decreased from 16.60 (Mar 24) to 3.02, marking a decrease of 13.58.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.95. This value is within the healthy range. It has decreased from 12.50 (Mar 24) to 2.95, marking a decrease of 9.55.
- For PBDIT Margin (%), as of Mar 25, the value is 20.92. This value is within the healthy range. It has decreased from 22.69 (Mar 24) to 20.92, marking a decrease of 1.77.
- For PBIT Margin (%), as of Mar 25, the value is 15.27. This value is within the healthy range. It has decreased from 20.66 (Mar 24) to 15.27, marking a decrease of 5.39.
- For PBT Margin (%), as of Mar 25, the value is 9.69. This value is below the healthy minimum of 10. It has decreased from 19.28 (Mar 24) to 9.69, marking a decrease of 9.59.
- For Net Profit Margin (%), as of Mar 25, the value is 9.47. This value is within the healthy range. It has decreased from 14.52 (Mar 24) to 9.47, marking a decrease of 5.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.27. This value is below the healthy minimum of 15. It has decreased from 18.57 (Mar 24) to 4.27, marking a decrease of 14.30.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 10. It has decreased from 17.93 (Mar 24) to 3.82, marking a decrease of 14.11.
- For Return On Assets (%), as of Mar 25, the value is 1.85. This value is below the healthy minimum of 5. It has decreased from 9.08 (Mar 24) to 1.85, marking a decrease of 7.23.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.76. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 0.76, marking an increase of 0.33.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.05. This value exceeds the healthy maximum of 1. It has increased from 0.62 (Mar 24) to 1.05, marking an increase of 0.43.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.20. It has decreased from 0.75 (Mar 24) to 0.20, marking a decrease of 0.55.
- For Current Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1.5. It has decreased from 1.29 (Mar 24) to 0.99, marking a decrease of 0.30.
- For Quick Ratio (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has decreased from 0.94 (Mar 24) to 0.82, marking a decrease of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 4. It has decreased from 2.90 (Mar 24) to 0.85, marking a decrease of 2.05.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.75. This value is within the healthy range. It has decreased from 16.55 (Mar 24) to 3.75, marking a decrease of 12.80.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.70. This value is below the healthy minimum of 3. It has decreased from 11.59 (Mar 24) to 2.70, marking a decrease of 8.89.
- For Enterprise Value (Cr.), as of Mar 25, the value is 188.07. It has increased from 125.03 (Mar 24) to 188.07, marking an increase of 63.04.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.70. This value exceeds the healthy maximum of 3. It has increased from 2.33 (Mar 24) to 9.70, marking an increase of 7.37.
- For EV / EBITDA (X), as of Mar 25, the value is 46.33. This value exceeds the healthy maximum of 15. It has increased from 10.27 (Mar 24) to 46.33, marking an increase of 36.06.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.41. This value exceeds the healthy maximum of 3. It has increased from 1.87 (Mar 24) to 7.41, marking an increase of 5.54.
- For Price / BV (X), as of Mar 25, the value is 3.34. This value exceeds the healthy maximum of 3. It has increased from 2.39 (Mar 24) to 3.34, marking an increase of 0.95.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.41. This value exceeds the healthy maximum of 3. It has increased from 1.87 (Mar 24) to 7.41, marking an increase of 5.54.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.01, marking a decrease of 0.06.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Auro Laboratories Ltd:
- Net Profit Margin: 9.47%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.82% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.27% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.7
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.82
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 152 (Industry average Stock P/E: 52.88)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.05
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.47%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | K-56, M.I.D.C. Industrial Area, Palghar District Maharashtra 401506 | auro@aurolabs.com http://www.aurolabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sharat Deorah | Chairman & Managing Director |
| Mr. Kiran Suresh Kulkarni | Whole Time Director |
| Mr. Siddhartha Deorah | Whole Time Director |
| Mr. Mahendra Kumar Daga | Ind. Non-Executive Director |
| Mrs. Kavita Vijayakant Sharma | Ind. Non-Executive Director |
| Mr. Vishal Kailashchandra Jhunjhunwala | Ind. Non-Executive Director |